CGTXHIGH SIGNALFINANCIAL10-K

CGTX eliminated going concern language while significantly strengthening its balance sheet through what appears to be a major equity raise, increasing outstanding shares by 44% and cash position by 47%.

The removal of "substantial doubt about our ability to continue as a going concern" language represents a material improvement in the company's financial stability and survival prospects. The simultaneous 44% increase in outstanding shares (from 62M to 89M) and substantial cash increase suggests a successful equity financing that has temporarily resolved immediate liquidity concerns, though this comes at the cost of significant dilution to existing shareholders.

Comparing 2026-03-26 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

CGTX dramatically strengthened its financial position with current assets growing 62% to $48M and stockholders' equity surging 83% to $34.3M, primarily driven by increased cash reserves. The company improved its burn rate with operating cash flow losses decreasing 14% to $24.6M and net losses improving 31% to $23.5M, while maintaining minimal capital expenditures. Overall, the financial picture signals a successful capital raise that has extended the company's runway and eliminated immediate going concern issues, though at the cost of substantial shareholder dilution.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-97.3%
$147K$4K

Capex reduced 97.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
+82.8%
$18.8M$34.3M

Equity base grew 82.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+62.4%
$29.6M$48.0M

Current assets grew 62.4% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+60.1%
$30.2M$48.4M

Asset base grew 60.1% — expansion through organic growth, acquisitions, or capital deployment.

Cash & Equivalents
Balance Sheet
+47.2%
$25.0M$36.8M

Cash position surged 47.2% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
+30.9%
-$34.0M-$23.5M

Net income grew 30.9% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
+25%
$11.1M$13.9M

Current liabilities rose 25% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+22.9%
$11.5M$14.1M

Liabilities increased 22.9% — monitor debt-to-equity ratio and interest coverage.

Operating Cash Flow
Cash Flow
+13.6%
-$28.5M-$24.6M

Operating cash flow grew 13.6% — strong conversion of earnings to cash, healthy business fundamentals.

Operating Income
P&L
+11.4%
-$54.0M-$47.8M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-20
ADDED
The number of outstanding shares of the Registrant s Common Stock as of March 20, 2026, was 89,353,773 .
The Company s initial focus was on the development of zervimesine for the treatment of AD.
Top-line results from the Company s Phase 2 COG0201 (SHINE) study of zervimesine in mild-to-moderate AD were reported in 2024.
As of October 15, 2025, approximately 782 subjects have received zervimesine in our clinical trials, including people with AD, DLB and dry age-related macular degeneration, or AMD.
Based on proteomic evidence generated from the Company s clinical programs in Alzheimer s disease and supported by in vitro findings, the company initiated the Phase 2 COG2201 (MAGNIFY) clinical study of zervimesine for the treatment of geographic atrophy secondary to dry AMD.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the Registrant s Common Stock as of March 17, 2025, was 61,972,946 .
presidential administration, inflation, tariffs, or uncertainty caused by political violence and unrest, including ongoing global and regional conflicts; developments relating to our competitors and our industry; and other risk and uncertainties, including those described in Item 1A Risk Factors in this Annual Report.
There is substantial doubt about our ability to continue as a going concern.
Concentration of our capital stock ownership with our directors and their affiliated entities and our executive officers will limit stockholders abilities to influence certain corporate matters.
The company s initial focus has been on the development of zervimesine for the treatment of Alzheimer s disease.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →